HER2 alterations are rare in NSCLC, but getting testing and treatment right is critical. Join this live, case-based webinar to learn when to test, explore new HER2-targeted therapies, & speed the path from detection to the right treatment.
Join us as we dive into the evolving pharmacologic landscape for PF and discuss strategies for clinical decision-making in light of these pivotal developments.
Enhance your expertise in MASH diagnosis and management with this one-of-a-kind preceptorship. Join us for a two-part training experience designed to elevate your skills—both in foundational learning and in-clinic shadowing. Apply today!
Join us for an engaging TheraTalk featuring an expert panel of neurologists and neuromuscular specialists from the US, Canada, and Europe as they explore the evolving landscape of MMN care.
Systemic mastocytosis (SM) is a rare disease marked by abnormal mast cell accumulation in the skin & other organs. Join this live webinar to learn how to recognize SM in dermatology practice, improve diagnosis & referrals.
Join us as they review current evidence on neoadjuvant, adjuvant, and perioperative approaches, discuss biomarker-driven treatment selection, and explore strategies to mitigate treatment-related toxicities through coordinated, team-based care.
Join us in the first session of the Hot Topics in Genitourinary Cancer series for an interactive live webinar designed to support oncologists and urologists in navigating this rapidly evolving treatment landscape.
$2495 includes 2 years Online Access + Live Hands-On with 2 Certificates (code NN204 at checkout) ✅Taught by Two Aesthetic MD's who oversee NP's ✅Max. 4 Providers per class ✅20u BTX and 1cc Filler included ⭐2026 aesthetic-training.com Top Pick
Live online
Tuesday, February 10, 6:00 - 9:00 pm
Contact Hours: 2.0
Registration Fee:
On or Before December 22 $49
After December 22 $69
Join our live national webinar led by expert oncologists and eye specialists to master the multidisciplinary management of ocular adverse events that some patients may experience when receiving ADCs and targeted therapies for cancer treatment.
